CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.09 USD
-0.17 (-0.30%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $56.05 -0.04 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRSP 56.09 -0.17(-0.30%)
Will CRSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
New Strong Sell Stocks for August 1st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Other News for CRSP
Cathie Wood Loads Up Millions on Google, AMD in Bold ARK Shift
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Undercovered Dozen: Power Solutions, Porsche, B2Gold And More
Cathie Wood Doesn't Need Tesla To Win—ARKK Delivers A Blowout While EV Giant Idles
CRSP September 5th Options Begin Trading